I think most of you know that the reason we haven’t been posting much the last three years is that Shou-Ching and I launched a biotech company, Angiex, in 2015 with the goal of creating a breakthrough cancer therapy.
Our drug is close to being finalized, and it is performing remarkably well. We have effectively regressed every tumor we’ve tested in rodents. There is good therapeutic margin in both mice and rats, and the drug is well tolerated in monkeys. There’s every reason to be optimistic it will do well in humans. There’s also reason to believe it will effectively treat the most malignant cancers, such as pancreatic cancer and liver cancer. The more aggressive the cancer, the better our drug works.
In the early days of the company, we applied to do an experiment in the US National Laboratory of the International Space Station, and were fortunate to receive funding for the experiment from Boeing and the Center for Advancement of Science in Space (CASIS) via the MassChallenge accelerator. We’re pleased to have received terrific support in developing the experiment from CASIS and BioServe Space Technologies. It’s now show time — the experiment is scheduled to launch this Friday, June 29, on SpaceX CRS-15.
CASIS came to our laboratory at LabCentral in Cambridge, Massachusetts, and made a very nice video explaining our experiment and some background about Angiex. We’re excited to share this glimpse at Angiex’s work. Enjoy!
via this link:
Recent Comments